IMNM Immunome Inc.

Nasdaq immunome.com


$ 15.80 $ 0.33 (2.13 %)    

Thursday, 06-Nov-2025 14:10:20 EST
QQQ $ 615.00 $ -6.79 (-1.09 %)
DIA $ 470.09 $ -1.94 (-0.41 %)
SPY $ 672.54 $ -3.93 (-0.58 %)
TLT $ 89.70 $ 0.14 (0.16 %)
GLD $ 367.45 $ 0.15 (0.04 %)
$ 15.35
$ 15.40
$ 15.68 x 3
$ 15.76 x 1,398
$ 15.32 - $ 15.80
$ 5.15 - $ 17.87
1,282,215
na
1.34B
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-19-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunome-presented-preclinical-data-showing-its-proprietary-antibody-drug-conjugate-payload-hc74-overcomes-multiple-mechanisms-of-adc-resistance-including-payload-efflux-and-target-heterogeneity-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer th...

 goldman-sachs-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Tar...

 craig-hallum-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 guggenheim-reiterates-buy-on-immunome-maintains-25-price-target

Guggenheim analyst Michael Schmidt reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $25 price target.

 evercore-isi-group-initiates-coverage-on-immunome-with-outperform-rating-announces-price-target-of-18

Evercore ISI Group analyst Cory Kasimov initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces ...

 jp-morgan-maintains-overweight-on-immunome-lowers-price-target-to-22

JP Morgan analyst Brian Cheng maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $23 to $22.

 immunome-q1-eps-052-beats-068-estimate-sales-293m-beat-28571k-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.68) by 2...

 lake-street-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-23

Lake Street analyst Chad Messer initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 wedbush-reiterates-outperform-on-immunome-maintains-33-price-target

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.

 stephens--co-reiterates-overweight-on-immunome-maintains-30-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Immunome (NASDAQ:IMNM) with a Overweight and maintains $30 price target.

 guggenheim-maintains-buy-on-immunome-lowers-price-target-to-25

Guggenheim analyst Michael Schmidt maintains Immunome (NASDAQ:IMNM) with a Buy and lowers the price target from $35 to $25.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION